Christopher J VandenBussche1, Derek B Allison1, Mindy K Graham1, Vivek Charu1, Anne Marie Lennon2,3, Christopher L Wolfgang2,4, Ralph H Hruban1,4, Christopher M Heaphy1,4. 1. Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland. 2. Department of Surgery, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland. 3. Department of Gastroenterology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland. 4. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
Abstract
BACKGROUND: Pancreatic neuroendocrine tumors (PanNETs) frequently use the alternative lengthening of telomeres (ALT) pathway for telomere maintenance. ALT is strongly correlated with α thalassemia-mental retardation, X linked (ATRX), and death domain-associated protein 6 (DAXX) alterations and a poor prognosis in patients with primary PanNET. Because fine-needle aspiration (FNA) is a noninvasive way to sample tumors, the authors evaluated whether they could accurately detect ALT and loss of ATRX/DAXX in a primary PanNET cohort of FNAs. METHODS: All preoperative FNA cytology cases (2005-2016) with adequate remnant FNA cell block material were assessed for ALT by telomere-specific fluorescence in situ hybridization and for ATRX and DAXX protein expression by immunohistochemistry. For 21 patients who underwent tumor resection, the resected specimen also was assessed to determine the concordance between the FNA and surgical specimens. RESULTS: In the primary PanNET cohort of 65 FNAs, ALT was detected in 15 specimens (23%). Although all ATRX-negative and DAXX-negative tumors were ALT-positive, 3 of 14 (21%) ALT-positive tumors did not exhibit nuclear loss of either ATRX or DAXX. The ALT-positive tumors were associated with larger radiographic size (4.9 vs 2.4 cm, on average; P < .05) and higher grade (P < .05). Overall, there was 100% concordance in ALT status and ATRX/DAXX immunohistochemistry results between the FNA and surgical specimens. CONCLUSIONS: Both ALT and loss of ATRX/DAXX can be accurately performed on FNA specimens with adequate material. Because ALT is a fundamental mechanism of pathogenesis, the ability to determine ALT in small biospecimens has implications for the design of clinical trials. Cancer Cytopathol 2017;125:544-51.
BACKGROUND:Pancreatic neuroendocrine tumors (PanNETs) frequently use the alternative lengthening of telomeres (ALT) pathway for telomere maintenance. ALT is strongly correlated with α thalassemia-mental retardation, X linked (ATRX), and death domain-associated protein 6 (DAXX) alterations and a poor prognosis in patients with primary PanNET. Because fine-needle aspiration (FNA) is a noninvasive way to sample tumors, the authors evaluated whether they could accurately detect ALT and loss of ATRX/DAXX in a primary PanNET cohort of FNAs. METHODS: All preoperative FNA cytology cases (2005-2016) with adequate remnant FNA cell block material were assessed for ALT by telomere-specific fluorescence in situ hybridization and for ATRX and DAXX protein expression by immunohistochemistry. For 21 patients who underwent tumor resection, the resected specimen also was assessed to determine the concordance between the FNA and surgical specimens. RESULTS: In the primary PanNET cohort of 65 FNAs, ALT was detected in 15 specimens (23%). Although all ATRX-negative and DAXX-negative tumors were ALT-positive, 3 of 14 (21%) ALT-positive tumors did not exhibit nuclear loss of either ATRX or DAXX. The ALT-positive tumors were associated with larger radiographic size (4.9 vs 2.4 cm, on average; P < .05) and higher grade (P < .05). Overall, there was 100% concordance in ALT status and ATRX/DAXX immunohistochemistry results between the FNA and surgical specimens. CONCLUSIONS: Both ALT and loss of ATRX/DAXX can be accurately performed on FNA specimens with adequate material. Because ALT is a fundamental mechanism of pathogenesis, the ability to determine ALT in small biospecimens has implications for the design of clinical trials. Cancer Cytopathol 2017;125:544-51.
Keywords:
alternative lengthening of telomeres (ALT); death domain-associated protein 6 (DAXX); pancreatic neuroendocrine tumors; α thalassemia-mental retardation, X linked (ATRX)
Authors: Robert L Dilley; Priyanka Verma; Nam Woo Cho; Harrison D Winters; Anne R Wondisford; Roger A Greenberg Journal: Nature Date: 2016-10-19 Impact factor: 49.962
Authors: Rachel Litman Flynn; Kelli E Cox; Maya Jeitany; Hiroaki Wakimoto; Alysia R Bryll; Neil J Ganem; Francesca Bersani; Jose R Pineda; Mario L Suvà; Cyril H Benes; Daniel A Haber; Francois D Boussin; Lee Zou Journal: Science Date: 2015-01-16 Impact factor: 47.728
Authors: Thorvardur R Halfdanarson; Joseph Rubin; Michael B Farnell; Clive S Grant; Gloria M Petersen Journal: Endocr Relat Cancer Date: 2008-06 Impact factor: 5.678
Authors: Lee H Wong; Hua Ren; Evan Williams; James McGhie; Soyeon Ahn; Marcus Sim; Angela Tam; Elizabeth Earle; Melissa A Anderson; Jeffrey Mann; K H Andy Choo Journal: Genome Res Date: 2009-02-05 Impact factor: 9.043
Authors: Aaron D Goldberg; Laura A Banaszynski; Kyung-Min Noh; Peter W Lewis; Simon J Elsaesser; Sonja Stadler; Scott Dewell; Martin Law; Xingyi Guo; Xuan Li; Duancheng Wen; Ariane Chapgier; Russell C DeKelver; Jeffrey C Miller; Ya-Li Lee; Elizabeth A Boydston; Michael C Holmes; Philip D Gregory; John M Greally; Shahin Rafii; Chingwen Yang; Peter J Scambler; David Garrick; Richard J Gibbons; Douglas R Higgs; Ileana M Cristea; Fyodor D Urnov; Deyou Zheng; C David Allis Journal: Cell Date: 2010-03-05 Impact factor: 41.582
Authors: Wenzel M Hackeng; Folkert H M Morsink; Leon M G Moons; Christopher M Heaphy; G Johan A Offerhaus; Koen M A Dreijerink; Lodewijk A A Brosens Journal: Diagn Cytopathol Date: 2019-12-17 Impact factor: 1.582
Authors: Antonio Pea; Jun Yu; Luigi Marchionni; Michael Noe; Claudio Luchini; Alessandra Pulvirenti; Roeland F de Wilde; Lodewijk A Brosens; Neda Rezaee; Ammar Javed; Peter Chianchiano; Stefano Gobbo; Paolo Regi; Roberto Salvia; Claudio Bassi; Jin He; Matthew J Weiss; John L Cameron; G Johan A Offerhaus; Ralph H Hruban; Rita T Lawlor; Aldo Scarpa; Christopher M Heaphy; Laura D Wood; Christopher L Wolfgang Journal: Ann Surg Date: 2020-03 Impact factor: 13.787
Authors: Tiago Bordeira Gaspar; Ana Sá; José Manuel Lopes; Manuel Sobrinho-Simões; Paula Soares; João Vinagre Journal: Genes (Basel) Date: 2018-05-03 Impact factor: 4.096